Olema Pharmaceuticals, Inc.
$16.58
▼
-0.4%
2026-04-21 08:37:01
olema.com
NMS: OLMA
Explore Olema Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.47 B
Current Price
$16.58
52W High / Low
$36.26 / $3.89
Stock P/E
—
Book Value
$5.88
Dividend Yield
—
ROCE
-37.1%
ROE
-36.61%
Face Value
—
EPS
$-1.87
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
131
Beta
2.18
Debt / Equity
0.88
Current Ratio
9.95
Quick Ratio
9.95
Forward P/E
-6.33
Price / Sales
—
Enterprise Value
$901.98 M
EV / EBITDA
-5.36
EV / Revenue
—
Rating
None
Target Price
$43
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Oragenics, Inc. | $0.71 | — | $3.19 M | — | -113.05% | -2.44% | $9.6 / $0.5 | $1.94 |
| 2. | Ernexa Therapeutics Inc. | $0.19 | — | $5.87 M | 0.34% | -342.48% | -6.87% | $4.05 / $0.18 | $0.31 |
| 3. | Black Diamond Therapeutics, Inc. | $3.05 | 7.84 | $175.3 M | — | 15.61% | 22.88% | $4.94 / $1.31 | $1.96 |
| 4. | ARS Pharmaceuticals, Inc. | $8.18 | — | $812.25 M | — | -62.2% | -92.33% | $18.9 / $6.66 | $1.15 |
| 5. | Xilio Therapeutics, Inc. | $8.45 | — | $49.46 M | — | -42.66% | -1.33% | $16.52 / $6.47 | $7.79 |
| 6. | Intellia Therapeutics, Inc. | $15.21 | — | $1.8 B | — | -59.74% | -53.48% | $28.25 / $6.8 | $5.77 |
| 7. | Anavex Life Sciences Corp. | $3.65 | — | $338.25 M | — | -54.15% | -33.63% | $13.99 / $2.61 | $1.37 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -50.08 M | -45.88 M | -47.86 M | -34.87 M | -36.77 M | — |
| Net Profit | -46.06 M | -42.22 M | -43.78 M | -30.39 M | -33.57 M | — |
| EPS in Rs | -0.53 | -0.48 | -0.5 | -0.35 | -0.39 | -0.6 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -178.7 M | -142.26 M | -104.96 M | -106.99 M |
| Net Profit | -162.45 M | -129.47 M | -96.66 M | -104.79 M |
| EPS in Rs | -1.86 | -1.49 | -1.11 | -1.2 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 533.43 M | 450.98 M | 276.94 M | 215.65 M |
| Total Liabilities | 54.87 M | 42.02 M | 23.05 M | 18.1 M |
| Equity | 478.56 M | 408.96 M | 253.9 M | 197.55 M |
| Current Assets | 515.45 M | 438.47 M | 266.51 M | 208.9 M |
| Current Liabilities | 51.8 M | 41.76 M | 21.62 M | 16.55 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -146.72 M | -104.35 M | -83.73 M | -82.06 M |
| Investing CF | -155.76 M | -93.53 M | -4.85 M | 91.48 M |
| Financing CF | 211.3 M | 268.82 M | 133.41 M | 0.48 M |
| Free CF | -146.72 M | -104.51 M | -83.73 M | -82.43 M |
| Capex | — | -0.16 M | — | -0.36 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -33.95% | 7.76% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.